Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761

View: 1235 Download: 64

Editorial

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704

View: 1168 Download: 33 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):1050-1052. Published online July 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0546

View: 1696 Download: 38

Original Article

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 3517 Download: 333 Web of Science: 4 Crossref: 3

Editorial

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):677-681. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0418

View: 1817 Download: 38

Review

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(3):326-344. Published online April 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0155

View: 4297 Download: 171 Web of Science: 10 Crossref: 8

1 |

Viewed By 12261	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7276	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 6945	MAFLD: How is it different from NAFLD?
Viewed By 5590	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5375	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search